Amryt Pharma PLC Company Profile (LON:FAST)

Analyst Ratings

Consensus Ratings for Amryt Pharma PLC (LON:FAST) (?)
Ratings Breakdown: 1 Hold Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: N/A

Analysts' Ratings History for Amryt Pharma PLC (LON:FAST)
Show:
DateFirmActionRatingPrice TargetActions
6/10/2016Beaufort SecuritiesReiterated RatingSpeculative BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/26/2015Davy ResearchReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/10/2014Cantor Fitzgerald EuropeReiterated RatingBuyGBX 27View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/18/2014GoodbodyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Amryt Pharma PLC (LON:FAST)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Amryt Pharma PLC (LON:FAST)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Amryt Pharma PLC (LON:FAST)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Amryt Pharma PLC (LON:FAST)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/3/2015Friel,CathalInsiderBuy3,555,394GBX 4£142,215.76Tweet This Trade  Share This Trade on StockTwits
6/26/2015Friel,CathalInsiderBuy17,308,080GBX 0.04£6,923.23Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Social

About Amryt Pharma PLC

Amryt Pharma PLC logoAmryt Pharma plc, formerly Fastnet Equity plc, is a United Kingdom-based specialty pharmaceutical company. The Company focuses on developing and delivering treatments for patients with rare and orphan diseases. The Company's products include Episalvan and Imlan. The Company's products focus on developing somatostatin analogue (SSA) peptide medicines for patients with rare neuroendocrine diseases, including acromegaly and Cushing's disease. The Company's Episalvan is a prescription pharmaceutical product, which accelerates wound healing. The Company's Episalvan consists of two ingredients, such as betulin-based active ingredient and sunflower oil as the excipient. The Company's Imlan products have regenerative and anti-inflammatory properties. Betulin is the active ingredient in the Imlan products and functions as the stabilizer of the creams and lotions. The Company's Imlan Creme Pur consists of Betulin, oil and water ingredients.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: FAST
  • CUSIP:
Key Metrics:
  • Previous Close: $0.04
  • 50 Day Moving Average: $2.908
  • 200 Day Moving Average: $2.544
  • P/E Ratio: N/A
  • P/E Growth: 0.000
  • Market Cap: $16541.00
  • Current Year EPS Consensus Estimate: $-0.330 EPS
  • Next Year EPS Consensus Estimate: $N/A EPS
Additional Links: